000306359 001__ 306359
000306359 005__ 20260203143752.0
000306359 0247_ $$2doi$$a10.2967/jnumed.125.270850
000306359 0247_ $$2pmid$$apmid:41266252
000306359 0247_ $$2ISSN$$a0097-9058
000306359 0247_ $$2ISSN$$a0022-3123
000306359 0247_ $$2ISSN$$a0161-5505
000306359 0247_ $$2ISSN$$a1535-5667
000306359 0247_ $$2ISSN$$a2159-662X
000306359 037__ $$aDKFZ-2025-02571
000306359 041__ $$aEnglish
000306359 082__ $$a610
000306359 1001_ $$0P:(DE-HGF)0$$aBartel, Timo$$b0
000306359 245__ $$a[68Ga]Ga-FAPI-46 PET/CT of Patients with Gastrointestinal Stromal Tumors in Comparison to 2-[18F]FDG PET/CT and Contrast-Enhanced CT: Results from a Prospective Observational Study.
000306359 260__ $$aNew York, NY$$bSoc.$$c2026
000306359 3367_ $$2DRIVER$$aarticle
000306359 3367_ $$2DataCite$$aOutput Types/Journal article
000306359 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770125837_1877213
000306359 3367_ $$2BibTeX$$aARTICLE
000306359 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000306359 3367_ $$00$$2EndNote$$aJournal Article
000306359 500__ $$a2026 Feb 2;67(2):210-216
000306359 520__ $$aGastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Although contrast-enhanced CT (ceCT) and 2-[18F]FDG PET/CT remain standard imaging modalities, both exhibit limitations in detecting small peritoneal metastases and tumors with low metabolic activity. 68Ga-labeled fibroblast activation protein inhibitors (FAPIs) have shown promising results in various malignancies; however, comparative data on GISTs are limited. This study aimed to assess the diagnostic performance of [68Ga]Ga-FAPI-46 PET/CT in comparison with 2-[18F]FDG PET/CT and ceCT, including evaluation of interreader reproducibility and clinical impact. Methods: This study retrospectively reviewed 25 patients with histopathologically confirmed GISTs undergoing [68Ga]Ga-FAPI-46 PET/CT as part of a prospective observational study (NCT04571086). All patients (n = 25) underwent additional clinical 2-[18F]FDG PET/CT; ceCT was performed for 23 of 25 patients. Imaging was assessed per patient and per region (primary tumor, lymph nodes, and visceral and bone metastases), and a composite reference standard that included histopathology, follow-up imaging, and clinical data was applied. Interreader agreement, stratified by experience level, was analyzed using Cohen κ (κCohen). Referring physicians completed questionnaires before and after imaging to determine clinical impact. Results: In total, 28 validated regions (n = 20 patients) were included in the diagnostic efficacy analysis. Per region, ceCT and [68Ga]Ga-FAPI-46 PET/CT demonstrated comparable sensitivity (83% vs. 81%), followed by 2-[18F]FDG PET/CT (65%). [68Ga]Ga-FAPI-46 PET/CT demonstrated the highest region-based positive predictive value (100%). The liver tumor-to-background ratio was significantly higher for [68Ga]Ga-FAPI-46 PET/CT than for 2-[18F]FDG PET/CT (median, 7.6 vs. 5.9; P = 0.034), whereas overall tumor uptake showed no significant difference. Changes in clinical management attributable to [68Ga]Ga-FAPI-46 PET/CT were observed for 6 of 24 patients (25%), including 1 major change. Interreader agreement for [68Ga]Ga-FAPI-46 PET/CT varied with reader experience, showing the highest concordance between high- and intermediate-experience readers (κCohen = 0.87 per patient and 0.47-1.00 across regions), whereas comparisons involving less experienced readers yielded lower agreement (κCohen = 0.00-0.60). Conclusion: [68Ga]Ga-FAPI-46 PET/CT demonstrated diagnostic sensitivity comparable to ceCT and superior to 2-[18F]FDG PET/CT for patients with GISTs. High diagnostic performance, especially in hepatic and peritoneal metastases, and relevant clinical impact support a role for [68Ga]Ga-FAPI-46 PET/CT as complementary imaging modality.
000306359 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000306359 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000306359 650_7 $$2Other$$a2-[18F]FDG PET/CT
000306359 650_7 $$2Other$$aGIST
000306359 650_7 $$2Other$$a[68Ga]Ga-FAPI-46 PET/CT
000306359 650_7 $$2Other$$adetection efficacy
000306359 7001_ $$0P:(DE-HGF)0$$aPabst, Kim M$$b1
000306359 7001_ $$0P:(DE-HGF)0$$aBarg, Christina$$b2
000306359 7001_ $$0P:(DE-HGF)0$$aBerliner, Christoph A$$b3
000306359 7001_ $$0P:(DE-HGF)0$$aHamacher, Rainer$$b4
000306359 7001_ $$0P:(DE-HGF)0$$aBauer, Sebastian$$b5
000306359 7001_ $$0P:(DE-HGF)0$$aFalkenhorst, Johanna$$b6
000306359 7001_ $$0P:(DE-HGF)0$$aKessler, Lukas$$b7
000306359 7001_ $$0P:(DE-HGF)0$$aNader, Michael$$b8
000306359 7001_ $$0P:(DE-HGF)0$$aBarbato, Francesco$$b9
000306359 7001_ $$0P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aSiveke, Jens$$b10$$udkfz
000306359 7001_ $$0P:(DE-HGF)0$$aHerrmann, Ken$$b11
000306359 7001_ $$0P:(DE-HGF)0$$aFendler, Wolfgang P$$b12
000306359 773__ $$0PERI:(DE-600)2040222-3$$a10.2967/jnumed.125.270850$$gp. jnumed.125.270850 -$$n2$$p210-216$$tJournal of nuclear medicine$$v67$$x0097-9058$$y2026
000306359 909CO $$ooai:inrepo02.dkfz.de:306359$$pVDB
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)026e0a55b968f360a3c349689ce8a99c$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000306359 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000306359 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000306359 9141_ $$y2025
000306359 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NUCL MED : 2022$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000306359 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NUCL MED : 2022$$d2025-01-01
000306359 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000306359 980__ $$ajournal
000306359 980__ $$aVDB
000306359 980__ $$aI:(DE-He78)ED01-20160331
000306359 980__ $$aUNRESTRICTED